BIOTRONIK Presents World's First ProMRI® Portfolio and Home Monitoring Technology at HRC 2012

Published: Sep 21, 2012

BICESTER, United Kingdom, September 21st, 2012—BIOTRONIK, a leading global manufacturer of innovative medical technology, is showcasing its new ProMRI® portfolio, BIOTRONIK Home Monitoring® and future technologies at Heart Rhythm Congress (Birmingham, UK) September 23-26, 2012.

BIOTRONIK has developed the world’s first implantable cardiac defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D) and cardiac resynchronization therapy pacemaker (CRT-P) with ProMRI® technology, enabling implantable device patients in the UK access to magnetic resonance (MR) scans for the first time.

In addition to being the world’s first ICDs, CRT-Ds and CRT-Ps approved for MR scans, BIOTRONIK’s new Lumax 740 and Evia HF-T series also include BIOTRONIK Home Monitoring®. BIOTRONIK Home Monitoring® technology allows physicians to remotely monitor the clinical and device status of their patients with implanted BIOTRONIK pacemakers, defibrillators or cardiac resynchronization therapy (CRT) devices no matter where they are, without any patient interaction for setup or data transmission. Studies have demonstrated that BIOTRONIK Home Monitoring® enables an early detection of atrial fibrillation and a significant reduction of hospitalizations (COMPAS1) and that it also reduces unnecessary and inappropriate shocks (ECOST2).

“At BIOTRONIK, we are committed to setting new standards in clinical excellence and we will be demonstrating this commitment at HRC 2012 with our innovative new technologies,” commented Christoph Böhmer, President International, BIOTRONIK. “We understand the needs of physicians and our products reflect this – our ProMRI® and BIOTRONIK Home Monitoring® technology provide innovative solutions that help physicians save and improve patients’ lives everyday and put BIOTRONIK firmly at the forefront of cardiac technology innovation.”

Quality Leads with proven reliability

To complete the ProMRI® portfolio, BIOTRONIK’s Linoxsmart ICD lead series and the Corox lead series are also the world´s first ICD/CRT-D and CRT-P leads approved for MR scans which gives physician a great wealth of choice and product combinations to suit every patient. The Lumax 740 ICD/CRT-Ds series and corresponding leads give physicians 112 possible lead-device combinations.

BIOTRONIK scientific session at HRC

Heart failure therapies will be the focus of BIOTRONIK’s scientific session at HRC, which is taking place on Monday 24th September. Renowned Cardiologist Dr. Christopher Plummer, Freeman Hospital, Newcastle, UK, will be chairing the session entitled, ‘The role of device diagnostic algorithms in the assessment and management of patients with heart failure’ which will include presentations and discussions about the current treatment of heart failure and the future of cardiac resynchronization therapy.

Visit BIOTRONIK at booth number: G2

About Heart Rhythm Congress 2012

Heart Rhythm Congress 2012 offers innovative and interactive learning for all involved in the management and treatment of cardiac arrhythmias. The congress boasts a full programme of scientific sessions along with Heart Rhythm UK Certificate of Accreditation courses, industry sponsored sessions and a patients’ day with a trade exhibition running throughout Discussion, debate, diversity, innovation and review - HRC 2012, the word in education in cardiac arrhythmias.


As one of the world’s leading manufacturers of cardiovascular medical devices, with several million devices implanted, BIOTRONIK is represented in over 100 countries by its global workforce of more than 5,600 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face, and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success—and deliver confidence and peace of mind to physicians and their patients worldwide.

For more information, visit:


1 Mabo P. et. al., Eur Heart J 2012, 33 (9): 1105-1111.

2 Kacet S, presentation at ESC Congress 2011 in Paris, France

Back to news